Infectious Disease
Leprosy
19
Pipeline Programs↗
6
Active Trials↗
8
Companies Involved↗
Leprosy is an emerging landscape with 19 programs across 8 companies. The most active players are Medicines Development for Global Health, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Bristol-Myers Squibb. 4 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 12
Phase 28
Analysis
Trial Status
17
clinical trials
Completed9 · 53%
Recruiting4 · 24%
Not yet recruiting2 · 12%
No longer available1 · 6%
Unknown status1 · 6%
Clinical Trials
Trial Activity
17 trials
Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy
Recruiting·—·Phase 2·NCT05243654·166 enrolled
Novel Interventions and Diagnostic Tests for Leprosy
Recruiting·—·N/A·NCT06222372·1,100 enrolled
Trial LEP-F1 + GLA-SE in Healthy Adult in Areas Endemic for Leprosy
Not yet recruiting·TThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)·Phase 1·NCT06627257·54 enrolled
Leprosy Skin Test Antigens Trial
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00128193·260 enrolled
Microcirculatory Impairment in Patients With Leprosy
Completed·—·N/A·NCT02085317·20 enrolled
Leprosy Skin Test Antigens Phase 1
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01920750·10 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)